HypothyroidismNCT07688824
The Effect of SPU on Hormonal and Cardiometabolic Factors
A study testing Soleus pushup exercise in people with Hypothyroidism and Hypertension, run by King Abdullah University Hospital at 1 site in Jordan.
Trial summary
The study examines the immediate effect of soleus pushup exercise on cardiometabolic and hormonal functions among hypothyroid patients. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Hypothyroidism, Hypertension, Healthy Adult
- What is being tested?
- Soleus pushup exercise
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteJordan
- Study dates
- 1 Mar 2025to 1 Feb 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Individuals aged 18-80,
- Patients diagnosed with hypothyroidism
- Patients diagnosed with hyperthyroidism
- Patients diagnosed with hypertension
- Patients diagnosed with diabetes mellitus
- Prediabetics
- Individuals who usually avoid regular physical/muscular activities involving lower limbs
- Age/gender matched apparently healthy individuals
Who cannot join
- Patients diagnosed with orthopedic diseases
- Patients diagnosed with cardiovascular diseases (other than hypertension)
- Patients diagnosed with renal dysfunction
Trial locations and contacts
1 site in 1 country.
About this study
The study examines the immediate effect of soleus pushup exercise on cardiometabolic and hormonal functions among hypothyroid patients.
Read the detailed description
The primary characteristic of hypothyroidism is sluggish metabolism, which is usually associated with abnormal weight gain, lethargy, constipation, heavy menstrual bleeding, hair loss, cold intolerance, and bradycardia. Importantly, these symptoms have been linked to reduced glucose tolerance and insulin sensitivity though glucose turnover and plasma insulin concentration are elevated. These metabolic changes result in hyperlipidemia, hypercholesterolemia, and elevated insulin resistance, and circulatory low-density lipoprotein cholesterol and total triglyceride levels. Hormonal replacement therapy, the primary treatment for hypothyroidism, partially restores the thyroid function and tappers down the disease symptoms. However, the therapy is associated a plethora of side effects, thus alternative therapies are warranted.
The effect of exercise on thyroid function and metabolism among patients with hypothyroidism is still equivocal. The soleus pushup exercise, a localized exercise that stimulates mainly oxidative metabolism, has been shown to have promising, favorable changes in systemic metabolism. Therefore, the current study compares metabolic and hormonal responses to soleus pushup exercise in patients with hypothyroidism versus healthy controls.
Patients diagnosed with hypothyroidism are recruited to participate in the study. Cardiovascular and circulatory, metabolic, and hormonal measures are determined from blood samples obtained from the patients. Age- and gender-matched healthy individuals are recruited to serve as controls.
- Conditions
- Hypothyroidism, Hypertension, Healthy Adult, Diabete Mellitus, Hyperthyroidism
- Being tested
- Soleus pushup exercise
- Keywords
- Hypothyroid, Soleus Pushup, Hormones
- Medical subject headings
- Hypothyroidism, Hypertension, Diabetes Mellitus, Hyperthyroidism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Soleus pushup exerciseBehavioural
The participants are given the soleus push-up exercise
| Study group | Role | What they receive |
|---|---|---|
| Hypothyroid patients | Experimental | Hypothyroid patients Receives: Behavioral: Soleus pushup exercise |
| Health controls | Experimental | Health controls Receives: Behavioral: Soleus pushup exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total cholesterol
Total cholesterol will be measured in blood and reported in mg/dL.
Measured: 3 hours
Triglycerides
Triglycerides will be measured in blood and reported in mg/dL.
Measured: 3 hours
HDL-C
High-density lipoprotein cholesterol will be measured in blood and reported in mg/dL.
Measured: 3 hours
LDL-C
Low-density lipoprotein cholesterol will be calculated using the lipid profile and reported in mg/dL.
Measured: 3 hours
VLDL-C
Very-low-density lipoprotein cholesterol will be calculated from triglycerides and reported in mg/dL.
Measured: 3 hours
Non-HDL cholesterol
Non-HDL cholesterol will be calculated as total cholesterol minus HDL-C and reported in mg/dL.
Measured: 3 hours
Apolipoprotein A-I
Apolipoprotein A-I will be measured in blood and reported in mg/dL.
Measured: 3 hours
Apolipoprotein B
Apolipoprotein B will be measured in blood and reported in mg/dL.
Measured: 3 hours
Lipoprotein(a)
Lipoprotein(a) will be measured in blood and reported in mg/dL or nmol/L, depending on the laboratory assay.
Measured: 3 hours
Fasting blood glucose
Fasting blood glucose will be measured in blood and reported in mg/dL.
Measured: 3 hours
Random blood glucose
Random blood glucose will be measured in blood and reported in mg/dL.
Measured: 3 hours
HbA1c
Glycated hemoglobin will be measured in blood and reported as a percentage.
Measured: 3 hours
Insulin
Insulin will be measured in blood and reported in µIU/mL or mIU/L, depending on the laboratory assay.
Measured: 3 hours
Glucagon
Glucagon will be measured in blood and reported in pg/mL.
Measured: 3 hours
Catecholamines
Catecholamines will be measured in blood and reported in pg/mL.
Measured: 3 hours
Thyroid-stimulating hormone
Thyroid-stimulating hormone will be measured in blood and reported in mIU/L or µIU/mL, depending on the laboratory assay.
Measured: 3 hours
Triiodothyronine
Triiodothyronine will be measured in blood and reported in ng/dL.
Measured: 3 hours
Thyroxine
Thyroxine will be measured in blood and reported in µg/dL.
Measured: 3 hours
Brain-derived neurotrophic factor
Brain-derived neurotrophic factor will be measured in blood and reported in pg/mL or ng/mL, depending on the laboratory assay.
Measured: 3 hours
Leptin
Leptin will be measured in blood and reported in ng/mL.
Measured: 3 hours
Adiponectin
Adiponectin will be measured in blood and reported in µg/mL.
Measured: 3 hours
Glucagon-like peptide
Glucagon-like peptide will be measured in blood and reported in pmol/L or pg/mL, depending on the laboratory assay.
Measured: 3 hours
Heart rate
Heart rate will be measured using the standard auscultatory method and reported in beats per minute.
Measured: 3 hours
Systolic blood pressure
Systolic blood pressure will be measured using the standard auscultatory method and reported in mmHg.
Measured: 3 hours
Diastolic blood pressure
Diastolic blood pressure will be measured using the standard auscultatory method and reported in mmHg.
Measured: 3 hours
Pulse pressure
Pulse pressure will be calculated as systolic blood pressure minus diastolic blood pressure and reported in mmHg.
Measured: 3 hours
Rate-pressure product
Rate-pressure product will be calculated as heart rate multiplied by systolic blood pressure and reported in bpm × mmHg.
Measured: 3 hours
Mean arterial pressure
Mean arterial pressure will be calculated as diastolic blood pressure plus one-third of pulse pressure and reported in mmHg.
Measured: 3 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jul 2026
- Study start1 Mar 2025
- Primary completion1 Feb 2026
- Study completion1 Feb 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypothyroidismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- The intervention is given to hypothyroid patients and healthy controls.
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- King Abdullah University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mahmoud Alomari, Jordan University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07688824
- Sponsor's protocol ID
- JUST121212
- Status last verified
- Jun 2026
- First submitted
- 24 May 2026
- Last updated
- 7 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of SPU on Hormonal and Cardiometabolic Factors
- ClinicalTrials.gov ID
- NCT07688824
- Acronym / sponsor ID
- JUST121212
- Conditions
- Hypothyroidism, Hypertension, Healthy Adult, Diabete Mellitus, Hyperthyroidism
- Keywords
- Hypothyroid, Soleus Pushup, Hormones
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- King Abdullah University HospitalUniversity, hospital or other
- Study start
- 1 Mar 2025 (actual)
- Primary completion
- 1 Feb 2026 (actual)
- Study completion
- 1 Feb 2026 (actual)
- First posted
- 7 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study examines the immediate effect of soleus pushup exercise on cardiometabolic and hormonal functions among hypothyroid patients.
Detailed description
The primary characteristic of hypothyroidism is sluggish metabolism, which is usually associated with abnormal weight gain, lethargy, constipation, heavy menstrual bleeding, hair loss, cold intolerance, and bradycardia. Importantly, these symptoms have been linked to reduced glucose tolerance and insulin sensitivity though glucose turnover and plasma insulin concentration are elevated. These metabolic changes result in hyperlipidemia, hypercholesterolemia, and elevated insulin resistance, and circulatory low-density lipoprotein cholesterol and total triglyceride levels. Hormonal replacement therapy, the primary treatment for hypothyroidism, partially restores the thyroid function and tappers down the disease symptoms. However, the therapy is associated a plethora of side effects, thus alternative therapies are warranted.
The effect of exercise on thyroid function and metabolism among patients with hypothyroidism is still equivocal. The soleus pushup exercise, a localized exercise that stimulates mainly oxidative metabolism, has been shown to have promising, favorable changes in systemic metabolism. Therefore, the current study compares metabolic and hormonal responses to soleus pushup exercise in patients with hypothyroidism versus healthy controls.
Patients diagnosed with hypothyroidism are recruited to participate in the study. Cardiovascular and circulatory, metabolic, and hormonal measures are determined from blood samples obtained from the patients. Age- and gender-matched healthy individuals are recruited to serve as controls.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The intervention is given to hypothyroid patients and healthy controls.
| Arm | Type | Receives |
|---|---|---|
| Hypothyroid patients | Experimental | Behavioral: Soleus pushup exerciseHypothyroid patients |
| Health controls | Experimental | Behavioral: Soleus pushup exerciseHealth controls |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Individuals aged 18-80,
- Patients diagnosed with hypothyroidism
- Patients diagnosed with hyperthyroidism
- Patients diagnosed with hypertension
- Patients diagnosed with diabetes mellitus
Key exclusion criteria (3 listed)
- Patients diagnosed with orthopedic diseases
- Patients diagnosed with cardiovascular diseases (other than hypertension)
- Patients diagnosed with renal dysfunction
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Soleus pushup exerciseThe participants are given the soleus push-up exercise | Behavioural | Health controls, Hypothyroid patients |
Primary outcome
Total cholesterol
Time frame: 3 hours
Total cholesterol will be measured in blood and reported in mg/dL.
Triglycerides
Time frame: 3 hours
Triglycerides will be measured in blood and reported in mg/dL.
HDL-C
Time frame: 3 hours
High-density lipoprotein cholesterol will be measured in blood and reported in mg/dL.
LDL-C
Time frame: 3 hours
Low-density lipoprotein cholesterol will be calculated using the lipid profile and reported in mg/dL.
VLDL-C
Time frame: 3 hours
Very-low-density lipoprotein cholesterol will be calculated from triglycerides and reported in mg/dL.
Non-HDL cholesterol
Time frame: 3 hours
Non-HDL cholesterol will be calculated as total cholesterol minus HDL-C and reported in mg/dL.
Apolipoprotein A-I
Time frame: 3 hours
Apolipoprotein A-I will be measured in blood and reported in mg/dL.
Apolipoprotein B
Time frame: 3 hours
Apolipoprotein B will be measured in blood and reported in mg/dL.
Lipoprotein(a)
Time frame: 3 hours
Lipoprotein(a) will be measured in blood and reported in mg/dL or nmol/L, depending on the laboratory assay.
Fasting blood glucose
Time frame: 3 hours
Fasting blood glucose will be measured in blood and reported in mg/dL.
Random blood glucose
Time frame: 3 hours
Random blood glucose will be measured in blood and reported in mg/dL.
HbA1c
Time frame: 3 hours
Glycated hemoglobin will be measured in blood and reported as a percentage.
Insulin
Time frame: 3 hours
Insulin will be measured in blood and reported in µIU/mL or mIU/L, depending on the laboratory assay.
Glucagon
Time frame: 3 hours
Glucagon will be measured in blood and reported in pg/mL.
Catecholamines
Time frame: 3 hours
Catecholamines will be measured in blood and reported in pg/mL.
Thyroid-stimulating hormone
Time frame: 3 hours
Thyroid-stimulating hormone will be measured in blood and reported in mIU/L or µIU/mL, depending on the laboratory assay.
Triiodothyronine
Time frame: 3 hours
Triiodothyronine will be measured in blood and reported in ng/dL.
Thyroxine
Time frame: 3 hours
Thyroxine will be measured in blood and reported in µg/dL.
Brain-derived neurotrophic factor
Time frame: 3 hours
Brain-derived neurotrophic factor will be measured in blood and reported in pg/mL or ng/mL, depending on the laboratory assay.
Leptin
Time frame: 3 hours
Leptin will be measured in blood and reported in ng/mL.
Adiponectin
Time frame: 3 hours
Adiponectin will be measured in blood and reported in µg/mL.
Glucagon-like peptide
Time frame: 3 hours
Glucagon-like peptide will be measured in blood and reported in pmol/L or pg/mL, depending on the laboratory assay.
Heart rate
Time frame: 3 hours
Heart rate will be measured using the standard auscultatory method and reported in beats per minute.
Systolic blood pressure
Time frame: 3 hours
Systolic blood pressure will be measured using the standard auscultatory method and reported in mmHg.
Diastolic blood pressure
Time frame: 3 hours
Diastolic blood pressure will be measured using the standard auscultatory method and reported in mmHg.
Pulse pressure
Time frame: 3 hours
Pulse pressure will be calculated as systolic blood pressure minus diastolic blood pressure and reported in mmHg.
Rate-pressure product
Time frame: 3 hours
Rate-pressure product will be calculated as heart rate multiplied by systolic blood pressure and reported in bpm × mmHg.
Mean arterial pressure
Time frame: 3 hours
Mean arterial pressure will be calculated as diastolic blood pressure plus one-third of pulse pressure and reported in mmHg.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
Related trials for Hypothyroidism
Not yet recruitingObservational study
Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Hypothyroidism, Psychometrics
RecruitingObservational study
Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation
Congenital Disorders of Glycosylation
Active, not recruitingPhase 4
Comparison of Two Timings of Levothyroxine Intake in Hypothyroid Patients: A Cross-over Randomized Control Trial
Hypothyroidism Primary
RecruitingObservational study
Understanding the Subnormal Rescue ofNeurological Development in Congenital Hypothyroidism (2022E5SZEM)
Congenital Hypothyroidism, Neurodevelopmental Disorders
RecruitingObservational study
Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years
Diabete Mellitus, Dyslipidaemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Soleus pushup exercise in people with Hypothyroidism and Hypertension, run by King Abdullah University Hospital at 1 site in Jordan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Jordan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total cholesterol (time frame: 3 hours). The study lists 28 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.